reports speaker fees from Astra Zeneca, Berlin Chemie, Biotronik, Boehringer Ingelheim, Bayer Health Care, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, Medtronic
229 DHEA formulated as a once-daily vaginal insert is approved by the FDA for the treatment of pain during sexual intercourse
Phase 2 and Phase 3 trials are expected to report results over the next two to four years, and regulatory discussions about potential addiction indications are already beginning
Many earlier-generation GHRPs, like GHRP-6 or GHRP-2, are effective at stimulating GH, but they can be a bit messy
The refreshing formula helps strengthen weak strands, reduce breakage, and improve overall hair vitality
Ethics declarations Conflict of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper